Scienture Holdings, Inc.
SCNX evidence brief
What we can confirm
- Market Cap:
- $14.3M
What it means
What to watch
Prepared research question
What matters most for SCNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SCNX
Scienture Holdings, Inc. (SCNX) is a holding company for specialty pharmaceutical subsidiary Scienture LLC, which commercializes two FDA-approved products for hypertension and opioid overdose and develops a pipeline of CNS and CVS candidates.
Key risk: Limited cash runway
Market Cap
$14.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Scienture Holdings, Inc. (SCNX) is a holding company for specialty pharmaceutical subsidiary Scienture LLC, which commercializes two FDA-approved products for hypertension and opioid overdose and develops a pipeline of CNS and CVS candidates.
- Acquired Scienture LLC on July 25, 2024, a specialty pharma company focused on cardiovascular and central nervous system diseases [sec · filed 2026-04-30].
- Two commercial products launched: ARBLI™ (hypertension) and REZENOPY™ (opioid overdose) [sec_mda · as of 2026-08-13].
- Cash & equivalents of $8.2M as of 2026-06-30 [sec]; management stated cash of $6.7M as of Dec 31, 2025 was expected to fund operations for at least 12 months [sec · filed 2026-04-30].
- Pipeline includes SCN-107 (post-surgical analgesia) under a worldwide exclusive license from Innocore Technologies [sec_mda · as of 2026-08-13].
- Limited revenue to date ($0.3M for six months ended June 30, 2026) and net loss of $2.8M for the same period [sec].
What works
- Two FDA-approved products (ARBLI™ and REZENOPY™) already launched, providing a revenue base and commercial infrastructure [sec_mda · as of 2026-08-13].
- Positive working capital of ~$5.2M as of Dec 31, 2025, a significant improvement from a deficit of $(1.6M) a year earlier [sec · filed 2026-04-30].
- Pipeline includes novel candidates for migraine, thrombosis, pain, and CNS/CVS diseases, with a strategy to advance them through clinical studies [sec_mda · as of 2026-08-13].
What to weigh
- Very limited revenue ($0.3M for H1 2026) and ongoing net losses ($2.8M for H1 2026) [sec].
- Cash runway is tight: $8.2M as of June 30, 2026, and management acknowledges the need to access additional capital to fund operations beyond 12 months [sec · filed 2026-04-30].
- Dependence on successful commercialization of only two products and uncertain ability to raise debt or equity on favorable terms [sec · filed 2026-04-30].
- Pipeline candidates are at early stages; SCN-107 still requires FDA clearance for initial safety/tolerability assessment [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Company acquired Scienture LLC on July 25, 2024
“On July 25, 2024, we acquired a wholly-owned subsidiary, Scienture LLC.”
SEC filings · April 30, 2026
Two commercial products launched
“We currently has two commercial products that have been launched and three primary product candidates in our development pipeline”
SEC MD&A · August 13, 2026
Cash position as of Dec 31, 2025
“cash of $6,662,008”
SEC filings · April 30, 2026
SCN-107 license from Innocore
“Innocore granted us a worldwide exclusive, milestone, royalty-bearing and sublicensable license to certain patent rights for the research and development of SCN-107”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash of $8.2M as of June 30, 2026 may not sustain operations beyond 12 months without additional funding [sec].
- Minimal revenue generation — Only $0.3M revenue in H1 2026, insufficient to cover operating costs [sec].
- Dependence on capital markets — No assurance that debt or equity financing will be available on favorable terms [sec · filed 2026-04-30].
- Early-stage pipeline — SCN-107 and other candidates require FDA clearance and clinical trials before commercialization [sec_mda · as of 2026-08-13].
What to watch
- Revenue growth from ARBLI™ and REZENOPY™ commercial sales [sec_mda · as of 2026-08-13].
- Ability to raise additional capital through debt or equity offerings [sec · filed 2026-04-30].
- FDA clearance and initiation of safety/tolerability study for SCN-107 [sec_mda · as of 2026-08-13].
- Progress of pipeline candidates for migraine, thrombosis, and pain through clinical development [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Scienture Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Scienture Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$381K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 432,186 | $123K |
| vanguard capital management llc | 408,091 | $116K |
| vanguard fiduciary trust co | 198,060 | $56K |
| ubs group ag | 107,833 | $31K |
| xtx topco ltd | 47,680 | $14K |
| commonwealth equity services, llc | 44,798 | $13K |
| two sigma securities, llc | 36,445 | $10K |
| jane street group, llc | 27,636 | $8K |
| private advisor group, llc | 15,002 | $4K |
| northern trust corp | 13,894 | $4K |
Showing top 10 of 13 institutional holders of Scienture Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 6.6%
- Days to cover
- 0.3
- Shares short
- 2,223,915
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SCNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Scienture Holdings, Inc.?
Scienture Holdings, Inc. (SCNX) is a holding company for specialty pharmaceutical subsidiary Scienture LLC, which commercializes two FDA-approved products for hypertension and opioid overdose and develops a pipeline of CNS and CVS candidates.
Who is the CEO of Scienture Holdings, Inc.?
Dr. Shankar Hariharan Ph.D. is the chief executive officer of Scienture Holdings, Inc. (SCNX).
Where is Scienture Holdings, Inc. headquartered?
Scienture Holdings, Inc. (SCNX) is headquartered in Commack, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.